Document Detail

Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype.
MedLine Citation:
PMID:  22258035     Owner:  NLM     Status:  MEDLINE    
There has been considerable interest in targeting cell cycle checkpoints particularly in emerging and alternative anticancer strategies. Here, we show that checkpoint abrogation by AZD7762, a potent and selective CHK1/2 kinase inhibitor enhances genotoxic treatment efficacy in immature KG1a leukemic cell line and in AML patient samples, particularly those with a complex karyotype, which display major genomic instability and chemoresistance. Furthermore, these data suggest that constitutive DNA-damage level might be useful markers to select AML patients susceptible to receive checkpoint inhibitor in combination with conventional chemotherapy. Moreover, this study demonstrates for the first time that AZD7762 inhibitor targets the CD34(+)CD38(-)CD123(+) primitive leukemic progenitors, which are responsible for the majority of AML patients relapse. Finally, CHK1 inhibition does not seem to affect clonogenic potential of normal hematopoietic progenitors.
Christine Didier; Cécile Demur; Fanny Grimal; Denis Jullien; Stéphane Manenti; Bernard Ducommun
Related Documents :
7477895 - Cyclic gmp-dependent protein kinase activation mediates inhibition of catecholamines se...
2446855 - Cyclic nucleotide phosphodiesterase activity in the quail oviduct: hormonal regulation ...
10870085 - Nitric oxide/cyclic gmp pathway attenuates atp-evoked intracellular calcium increase in...
22820035 - Aedescapa-pvk-1 displays diuretic and dose dependent antidiuretic potential in the larv...
9889195 - Pi 3-kinase gamma and protein kinase c-zeta mediate ras-independent activation of map k...
12506135 - Ca2+/calmodulin-dependent protein kinase ii stimulates c-fos transcription and dna synt...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-03-01
Journal Detail:
Title:  Cancer biology & therapy     Volume:  13     ISSN:  1555-8576     ISO Abbreviation:  Cancer Biol. Ther.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-04-06     Completed Date:  2012-10-15     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101137842     Medline TA:  Cancer Biol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  307-13     Citation Subset:  IM    
INSERM, U1037, Cancer Research Center of Toulouse, CNRS ERL 5294, Toulouse, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects,  genetics
Cell Cycle Checkpoints / drug effects
Cell Line, Tumor
Leukemia, Myeloid, Acute / drug therapy*,  enzymology*,  genetics,  pathology
Middle Aged
Molecular Targeted Therapy
Protein Kinase Inhibitors / pharmacology*
Protein Kinases / genetics,  metabolism*
Thiophenes / pharmacology*
Urea / analogs & derivatives*,  pharmacology
Reg. No./Substance:
0/3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide; 0/Protein Kinase Inhibitors; 0/Thiophenes; 57-13-6/Urea; EC 2.7.-/Protein Kinases; EC kinase 1

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vasculogenic mimicry and its clinical significance in medulloblastoma.
Next Document:  Effects of bisphenol A exposure on the proliferation and senescence of normal human mammary epitheli...